Here are the 8-K filings from Palomino Labs Inc (PALX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow PALX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PALX filings page.
Palomino Laboratories Inc. (PALX) amended its acquisition disclosures to add Vega Links’ audited financial statements and unaudited pro forma combined figures after the July 31, 2026 acquisition. Palomino issued 4,472,000 common shares for all of Vega Links’ issued shares, making it a wholly owned subsidiary.
For the six months ended June 30, 2026, pro forma revenue was $0 and net loss was $4,734,187, or $0.22 per share; for 2025, pro forma revenue was $0 and net loss was $10,855,778, or $1.49 per share. These illustrative results exclude potential integration costs and benefits, and the purchase-price allocation is preliminary.
Vega Links reported a $16,346 net loss for its period from inception through July 30, 2026, and $70,129 cash as of July 30. Its Strategic Development Agreement, which contemplated up to $2.0 million in milestone fees, was terminated in August without amounts earned or paid; Palomino funds its development directly. Vega Links held $254 cash on October 14, 2026, and management concluded Palomino’s funding alleviated substantial doubt about Vega Links’ ability to continue as a going concern for at least twelve months.
Palomino Laboratories Inc. completed a share exchange to acquire all 11,180,000 outstanding shares of Vega Links Inc., a developer of semiconductor integrated circuits for high-speed AI interconnects. In return, Palomino issued 4,472,000 shares of its common stock, reflecting an exchange rate of 0.4 Palomino share per Vega Links share.
The issued Palomino shares are subject to vesting, and certain former Vega Links stockholders face lock-up restrictions of up to three years after Palomino stock begins trading on OTC markets. The shares were issued in a private transaction relying on the Section 4(a)(2) Securities Act exemption.
Management states the transaction transforms Palomino into a comprehensive AI interconnect company and estimates that its addressable market expands by approximately 10x to more than $60 billion. Concurrently, Palomino appointed a new Chief Technology Officer and Chief Product Officer and added two veteran semiconductor executives to its Strategic Advisory Board to support its AI interconnect chipset roadmap.
Palomino Laboratories Inc. entered into a binding Letter of Intent on July 14, 2026 to acquire Vega Links Inc., an AI interconnect company. The proposed all-stock transaction contemplates issuing 4,472,000 Palomino common shares in exchange for all 11,180,000 outstanding Vega shares, reflecting a 1:2.5 exchange ratio.
The Letter of Intent sets an exclusivity period through September 30, 2026 for due diligence and negotiation of definitive agreements and includes business-conduct restrictions, confidentiality, standstill and cooperation covenants. The company states the final acquisition terms, including total consideration, remain subject to negotiation, and there is no assurance the transaction will be completed.
Management describes the combination as creating a broader AI interconnect platform across copper, MicroVCSEL and MicroLED technologies and estimates Palomino’s addressable market could increase about 10x, from roughly $6 billion to more than $60 billion. Following a closing, Palomino expects to appoint Vega leaders Karthik Gopalakrishnan as CTO and Rajesh Radhamohan as CPO.
Palomino Laboratories Inc. completed a second and final closing of a private stock offering to accredited investors. The company sold 470,000 shares of common stock at $4.00 per share, raising gross proceeds of $1,880,000.00. This followed an initial closing of 3,773,853 shares for $15,095,412.00 at the same price.
The unregistered offering relied on Section 4(a)(2) and Rule 506 of the Securities Act. Placement agent Laidlaw & Company (UK) Ltd. received cash fees based on invested amounts and was granted 374,761 five-year warrants with a $4.80 exercise price and weighted-average anti-dilution protection.
Palomino Laboratories Inc. entered into subscription agreements for a private placement of its common stock. On April 20, 2026, the company sold 3,773,853 shares at $4.00 per share, raising $15,095,412 in an initial closing, with the Offering permitted to reach up to $30,000,000 through additional closings by April 30, 2026.
Laidlaw & Company (UK) Ltd. will receive cash fees and expense reimbursements based on gross proceeds, plus warrants equal to 10% of shares sold to its introduced investors at a 120% exercise price. Investors received registration rights requiring Palomino to file resale registration statements and provide piggyback rights, giving a pathway to eventual public resale of the privately placed shares.